RecruitingPhase 2NCT07777536
Blood
Anaplastic thyroid carcinoma
15
studies recruiting now
as of 7 Sept 2026
106
studies registered in total
as of 7 Sept 2026
13
countries with a recruiting site
as of 7 Sept 2026
20 Aug 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2 / Phase 3NCT07440290
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
RecruitingPhase 2NCT05503797
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RecruitingPhase 1 / Phase 2NCT06814496
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
RecruitingPhase 2NCT06007924
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 15 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Anaplastic thyroid carcinoma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Anaplastic thyroid carcinoma
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
4 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 2Docetaxel (Beizray)
Phase 2Lenvatinib (Kisplyx)
Phase 2Doxorubicin Hydrochloride (Adriamycin)
Phase 2Pembrolizumab (Keytruda)
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).